Furthermore, studies in vitro and in vivo, genetically and pharmacologically, have revealed PTHrP’s causative effects in cancer progression of breast cancer [18], giant cell tumor of bone [19], prostate cancer [20], pancreatic cancer [21], and kidney cancer [22,23]. This evidence concerns the gene PTHLH and kidney cancer.